Immunitybio, Inc.

Congress has disclosed 2 buys and 1 sell of IBRX (Immunitybio, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

Round-trip watch Still on the books

Members who disclosed buying IBRX and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

3 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in IBRX — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

Of the congressional trades in IBRX, 0 coincided with corporate insiders moving the same way within 60 days, and 2 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.